DOCSLIB.ORG

The Roles of Fibroblast Growth Factor 22 in Development, Tissue Repair and Homeostasis, and the Associated Role of FGF Signalling in Skin Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Roles of Fibroblast Growth Factor 22 in Development, Tissue Repair and Homeostasis, and the Associated Role of FGF Signalling in Skin Cancer The roles of Fibroblast Growth Factor 22 in development, tissue repair and homeostasis, and the associated role of FGF signalling in skin cancer. Jarosz, Monika The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author For additional information about this publication click this link. https://qmro.qmul.ac.uk/jspui/handle/123456789/433 Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact [email protected] The roles of Fibroblast Growth Factor 22 in development, tissue repair and homeostasis, and the associated role of FGF signalling in skin cancer. Monika Jarosz This thesis is submitted in fulfilment of the requirements for the degree of Doctor of Philosophy University of London February 2010 Centre for Tumour Biology, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK DECLARATION OF AUTHORSHIP I hereby declare that the material presented in this thesis is the result of original work done by the author, Monika Jarosz, at the Department of Tumour Biology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. All external sources have been properly acknowledged. 2 Abstract Fibroblast Growth Factors (FGFs) play critical roles during development, tissue homeostasis and repair and in controlling cell proliferation, survival, migration and differentiation. Of the 22 mammalian FGFs, FGF22, a member of the FGF7/10/22 subfamily, is relatively understudied. I have investigated the in vivo functions of FGF22 in mice engineered to lack Fgf22. Fgf22 null animals were viable, fertile and did not display any obvious abnormalities. No differences in skin histology and pelage hair were observed, demonstrating that FGF22 is dispensable during embryogenesis and in unchallenged adult skin. Mice lacking FGF22 were able to heal acute wounds just as efficiently as wild type mice. However, classical two-step skin carcinogenesis challenge revealed that Fgf22 null mice developed considerably less papillomas than wild type mice. Interestingly, Fgf22 knockout mice displayed a significant reduction in body weight and I identified several novel sites of Fgf22 expression in the gastrointestinal tract. However, the morphology and function of various tested tissues of the digestive system were not affected by Fgf22 deletion and the mechanism underlying metabolic differences between Fgf22 wild type and knockout mice remains unknown. FGF22 signals through FGFR2b, a receptor tyrosine kinase that we recently have shown plays a tumour-suppressive role in the mouse skin. Another aspect of my project was to verify whether FGFR2 plays a similar role in human skin, by investigating squamous cell carcinoma (SCC) sections and cell lines isolated from patient SCCs. I observed differences in the pattern of anti-FGFR2 3 immunostaining of normal skin and tumours. Also, since it is well documented that mutations in FGFR2 arise in patients with different types of cancer, I screened DNA isolated from the cell lines and identified eleven different mutations in FGFR2. This study contributes towards a better understanding of the wide spectrum of FGF/FGFR activities and distinct regulatory functions in the biology of physiological and pathological processes. 4 All truths are easy to understand once they are discovered; the point is to discover them. Galileo Galilei Science never solves a problem without creating ten more. George Bernard Shaw 5 Acknowledgements I would like to gratefully acknowledge the enthusiastic supervision of Dr Richard Grose during this work. I am deeply thankful for his wise guidance, great support and encouragement. I want to express heart-felt gratitude to my dearest friends Magdalena Nowak- Musial, Sabari Vallath and Marcus Pearce for being there for me. I am additionally indebted to Magda for her work and expertise on the retinal aspect of my project. I would also like to thank Prof Ian Hart and all my colleagues from the lab, especially Maria, Bernardo, Silvia, Fieke, Mike, Antonio, Sally, Monica, Carine, Louise, Katie and Ireny. It has been a great pleasure and fun working with you. Several people have played a decisive role in saving me from leaving FGFs forever. Richard, Sabari, Mum and Dad - without your support, care and consideration this PhD thesis would not have been written. I am very thankful to you all. I would also like to thank Barbara, Rob and Jenny for all their hard work in the animal unit at Clare Hall Laboratories, CRUK. Lastly, I would like to thank St Bartholomew's and the Royal London Charitable Foundation for the funding provided which allowed me to complete this work and fulfil my dreams. Dedication I would like to dedicate this thesis to my family, my mother Alicja, my father Jozef and my sister Kasia to whom I owe my deepest gratitude for their endless love and constant encouragement in pursuing my goals. 6 TABLE OF CONTENTS Title page 1 Declaration 2 Abstract 3 Acknowledgements 6 Dedication 6 Table of contents 7 List of figures 13 List of tables 16 Chapter 1: Introduction 17 1.1.1 The fibroblast growth factor family 18 1.1.2 FGF7 subfamily 20 1.2 Fibroblast growth factor receptors – structure and specificity 21 1.3 FGF signalling 24 1.4 FGF mutations in human birth defects 27 1.5 Fgf knockout mice phenotypes 30 7 1.6 FGFs in skin development and homeostasis 34 1.6.1 Skin structure 34 1.6.2 FGFs and wound healing 38 1.6.3 FGFs and skin carcinogenesis 44 1.7 FGFs and their receptors in cancer 46 1.8 Therapeutic approaches 48 Aims 50 Hypothesis 50 Chapter 2: Materials and methods 51 2.1 Materials 52 2.1.1 Chemicals and other consumables 52 2.1.2 Antibodies 57 2.1.3 Primers 59 2.1.3.1 Primers for genotyping 59 2.1.3.2 Primers for RT-PCR 60 2.1.3.3 Primers for Real-Time RT-PCR 60 2.1.3.4 Primers for sequencing 62 2.1.3.5 Mycoplasma screening primers 62 2.1.3.6 Loading control primers 62 2.2 Mice 63 2.2.1 Conditional knockout mice (K5-R2b null) 63 2.2.2 Creation of Fgf22 knockout mice 64 2.3 Genotyping, PCR and DNA gel electrophoresis 65 2.3.1 DNA isolation 65 8 2.3.2 Polymerase chain reaction (PCR) 66 2.3.3 Electrophoresis 67 2.4 RNA isolation 68 2.5 cDNA synthesis 69 2.6 PCR product digestion 71 2.7 Real-time Polymerase Chain Reaction (PCR) 73 2.8 TOPO cloning 75 2.8.1 TOPO TA cloning reaction 76 2.8.2 Transforming One Shot TOP10 competent cells 76 2.8.3 Plating bacteria 77 2.8.4 DNA Miniprep 77 2.8.5 PCR identification of positive clones 78 2.8.6 Plasmid extraction 78 2.9 Sequencing 79 2.9.1 Routine sequencing 79 2.9.2 Mutation screening sequencing 80 2.9.2.1 Labelling 80 2.9.2.2 Precipitation of labelled products 81 2.10 Cell lysis and Western blotting 81 2.10.1 Cell Lysis 81 2.10.2 Determination of protein concentration 82 2.10.3 Gel electrophoresis 82 2.10.4 Western blotting 83 2.10.5 FGFR2 Western blot 83 2.11 Genomic DNA extraction from cell monolayers 84 2.12 Southern Blotting 85 2.12.1 ES cell screening probe preparation 87 9 2.12.2 Probe labelling 88 2.12.3 Hybridisation 88 2.13 Tissue fixation and wax embedding 89 2.13.1 Eye dissection 89 2.13.2 Oesophagus and stomach dissection 90 2.14 Tail epidermis whole-mounts 91 2.15 Immunohistochemistry 92 2.15.1 -FGFR-2 antibody 92 2.15.2 -BrdU antibody 93 2.15.3 -p63 antibody 94 2.15.4 -Loricrin antibody 95 2.15.5 -Keratin14 antibody 96 2.16 Alcian Blue and Alizarin Red skeletal staining 96 2.17 Sirius red staining 97 2.18 ELISA 98 2.18.1 Sample collection and storage 95 2.18.2 Assay procedure 99 2.19 Basic cell culture 100 2.19.1 General principles 101 2.19.2 Tissue culture media and solutions 101 2.19.2.1 CR-UK stock media 101 2.19.2.2 Human SCC keratinocyte medium 101 2.19.2.3 Early passage HaCaT keratinocyte medium 102 2.19.2.4 Primary murine keratinocyte media 102 2.19.2.4.1 Preparation of calcium free FBS 102 2.19.3 Mycoplasma screening 102 2.19.4 Early passage HaCaT keratinocyte cell culture 104 10 2.19.5 Primary murine keratinocyte cell culture 104 2.19.5.1 Coating flasks for keratinocyte cell culture 106 2.19.5.2 Passaging primary keratinocytes 106 2.19.6 Storage and recovery of liquid nitrogen stocks 107 2.19.6.1 Cryopreservation of cultured cells 107 2.19.6.2 Thawing cell stocks 107 2.20 In vitro wound closure assay - Scratch assay 108 2.21 Organotypic co-culture 108 2.22 Mouse growth curves 110 2.23 In vivo wound healing 110 2.24 Topical administration of DMBA/PMA to mice 111 2.25 Micro CT 113 2.26 Ethical regulations 113 Chapter 3: Fibroblast growth factor 22 115 3.1 Introduction 115 3.1.1 Fgf22 expression profile 115 3.1.2 FGF signalling in hair follicle morphogenesis 116 3.1.3 FGFs in wound healing 119 3.1.4 FGFs in the brain 121 3.1.5 Other sites of Fgf22 expression 123 3.1.6 Properties of FGF22 protein 124 3.2 Results 127 3.2.1 Generation of Fgf22 knockout mice 127 3.2.2 Characterisation of Fgf22 knockout mice 134 3.3 Discussion 171 11 3.4 Future directions 180 Chapter 4: Fibroblast growth factor receptor 2 182 4.1 Introduction 183 4.1.1 The role of FGFRs in carcinogenesis 183 4.1.2 FGFR2 as a tumour suppressor 183 4.1.3 FGFR2 as an oncogene 187 4.1.4 FGFR2 germline mutations 191 4.1.5 Potential therapeutic approaches 193 4.2 Results 195 4.2.1 FGFR2 genomic sequence in SCC keratinocyte cell lines 195 4.2.2 FGFR2 mutation screening 198 4.2.3 SCC cell lines express the FGFR2IIIb splice isoform 204 4.2.4 FGFR2 expression in normal human skin and human 211 squamous cell carcinoma 4.3 Discussion 214 4.4 Future directions 219 Chapter 5: Final discussion 222 Appendix 232 Bibliography 248 12 LIST OF FIGURES Chapter 1: Introduction Figure 1.1 Fibroblast growth factor family.
Load more

Recommended publications
  • FGF Signaling Network in the Gastrointestinal Tract (Review)
    163-168 1/6/06 16:12 Page 163 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 163-168, 2006 163 FGF signaling network in the gastrointestinal tract (Review) MASUKO KATOH1 and MASARU KATOH2 1M&M Medical BioInformatics, Hongo 113-0033; 2Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received March 29, 2006; Accepted May 2, 2006 Abstract. Fibroblast growth factor (FGF) signals are trans- Contents duced through FGF receptors (FGFRs) and FRS2/FRS3- SHP2 (PTPN11)-GRB2 docking protein complex to SOS- 1. Introduction RAS-RAF-MAPKK-MAPK signaling cascade and GAB1/ 2. FGF family GAB2-PI3K-PDK-AKT/aPKC signaling cascade. The RAS~ 3. Regulation of FGF signaling by WNT MAPK signaling cascade is implicated in cell growth and 4. FGF signaling network in the stomach differentiation, the PI3K~AKT signaling cascade in cell 5. FGF signaling network in the colon survival and cell fate determination, and the PI3K~aPKC 6. Clinical application of FGF signaling cascade in cell polarity control. FGF18, FGF20 and 7. Clinical application of FGF signaling inhibitors SPRY4 are potent targets of the canonical WNT signaling 8. Perspectives pathway in the gastrointestinal tract. SPRY4 is the FGF signaling inhibitor functioning as negative feedback apparatus for the WNT/FGF-dependent epithelial proliferation. 1. Introduction Recombinant FGF7 and FGF20 proteins are applicable for treatment of chemotherapy/radiation-induced mucosal injury, Fibroblast growth factor (FGF) family proteins play key roles while recombinant FGF2 protein and FGF4 expression vector in growth and survival of stem cells during embryogenesis, are applicable for therapeutic angiogenesis. Helicobacter tissues regeneration, and carcinogenesis (1-4).
    [Show full text]
  • Targeting Fibroblast Growth Factor Pathways in Endometrial Cancer
    Curr Probl Cancer 41 (2017) 37–47 Contents lists available at ScienceDirect Curr Probl Cancer journal homepage: www.elsevier.com/locate/cpcancer Targeting fibroblast growth factor pathways in endometrial cancer Boris Winterhoff, MDa, Gottfried E. Konecny, MDb,* article info abstract Novel treatments that improve outcomes for patients with Keywords: recurrent or metastatic endometrial cancer (EC) remain an Endometrial cancer unmet need. Aberrant signaling by fibroblast growth factors Fibroblast growth factor (FGFs) and FGF receptors (FGFRs) has been implicated in Angiogenesis several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical develop- ment for the treatment of EC. & 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Introduction Endometrial cancer (EC) is the most common gynecologic cancer, with 54,870 new cases and 10,170 related deaths estimated for the United States in 2015.1 Localized disease is often curable with surgery and the 5-year relative survival rate for patients diagnosed with early-stage EC is high.1-3 However, for patients who present with metastatic disease or experience a recurrence, prognosis is poor.1-3 Response of metastatic EC to standard therapies (eg, adjuvant radiotherapy, brachytherapy, or chemotherapy) is limited and overall survival for most patients with recurrent or metastatic disease is r1year.2-4 Thus, novel treatment options for this disease remain an unmet need.
    [Show full text]
  • Fibroblast Growth Factor Receptors 1 and 2 in Keratinocytes Control the Epidermal Barrier and Cutaneous Homeostasis
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2010 Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis Jingxuan Yang Michael Meyer Anna-Katharina Müller Friederike Böhm Richard Grose See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Authors Jingxuan Yang, Michael Meyer, Anna-Katharina Müller, Friederike Böhm, Richard Grose, Tina Dauwalder, Francois Verrey, Manfred Kopf, Juha Partanen, Wilhelm Bloch, David M. Ornitz, and Sabine Werner JCB: Article Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis 1 1 1 1 2 3 Jingxuan Yang, Michael Meyer, Anna-Katharina Müller, Friederike Böhm, Richard Grose, Tina Dauwalder, Downloaded from https://rupress.org/jcb/article-pdf/188/6/935/807652/jcb_200910126.pdf by Washington University In St. Louis Libraries user on 16 December 2019 Francois Verrey,3 Manfred Kopf,4 Juha Partanen,5 Wilhelm Bloch,6 David M. Ornitz,7 and Sabine Werner1 1Department of Biology, Institute of Cell Biology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland 2Centre for Tumour Biology, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London SW3 6JB, England, UK 3Institute of Physiology and Center for Integrative Human Physiology, University of Zurich, 8057 Zurich, Switzerland 4Department of Environmental Sciences, Institute of Integrative Biology, Eidgenössische Technische Hochschule Zurich, 8952 Schlieren, Switzerland 5Institute of Biotechnology, Viikki Biocenter, 00014 Helsinki, Finland 6Department of Molecular and Cellular Sport Medicine, German Sport University Cologne, 50933 Cologne, Germany 7Department of Developmental Biology, Washington University School of Medicine, St.
    [Show full text]
  • Genetic Insights Into the Mechanisms of Fgf Signaling
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Genetic insights into the mechanisms of Fgf signaling J. Richard Brewer, Pierre Mazot, and Philippe Soriano Department of Developmental and Regenerative Biology, Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, New York, New York 10029, USA The fibroblast growth factor (Fgf) family of ligands and re- Fgf signaling is therefore important to appreciate many as- ceptor tyrosine kinases is required throughout embryonic pects of Fgf biology and disease. and postnatal development and also regulates multiple Many of the developmental functions of Fgf signaling homeostatic functions in the adult. Aberrant Fgf signaling seem to be conserved between mice and humans. This causes many congenital disorders and underlies multiple is evident by the striking phenotypic similarities between forms of cancer. Understanding the mechanisms that gov- human congenital disorders caused by alterations in ern Fgf signaling is therefore important to appreciate Fgf signaling and their corresponding mouse models. many aspects of Fgf biology and disease. Here we review Conserved developmental requirements have been dem- the mechanisms of Fgf signaling by focusing on genetic onstrated in skeletal growth, palate closure, limb pattern- strategies that enable in vivo analysis. These studies sup- ing, ear development, cranial suture ossification, neural port an important role for Erk1/2 as a mediator of Fgf sig- development, and the hair cycle (Hebert et al. 1994; Rous- naling in many biological processes but have also provided seau et al. 1994; Shiang et al. 1994; Wilkie et al. 1995; Par- strong evidence for additional signaling pathways in trans- tanen et al.
    [Show full text]
  • Expression of Fgfs During Early Mouse Tongue Development
    Gene Expression Patterns 20 (2016) 81e87 Contents lists available at ScienceDirect Gene Expression Patterns journal homepage: http://www.elsevier.com/locate/gep Expression of FGFs during early mouse tongue development * Wen Du a, b, Jan Prochazka b, c, Michaela Prochazkova b, c, Ophir D. Klein b, d, a State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, China b Department of Orofacial Sciences and Program in Craniofacial Biology, University of California San Francisco, San Francisco, CA 94143, USA c Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic d Department of Pediatrics and Institute for Human Genetics, University of California San Francisco, San Francisco, CA 94143, USA article info abstract Article history: The fibroblast growth factors (FGFs) constitute one of the largest growth factor families, and several Received 29 September 2015 ligands and receptors in this family are known to play critical roles during tongue development. In order Received in revised form to provide a comprehensive foundation for research into the role of FGFs during the process of tongue 13 December 2015 formation, we measured the transcript levels by quantitative PCR and mapped the expression patterns by Accepted 29 December 2015 in situ hybridization of all 22 Fgfs during mouse tongue development between embryonic days (E) 11.5 Available online 31 December 2015 and E14.5. During this period, Fgf5, Fgf6, Fgf7, Fgf9, Fgf10, Fgf13, Fgf15, Fgf16 and Fgf18 could all be detected with various intensities in the mesenchyme, whereas Fgf1 and Fgf2 were expressed in both the Keywords: Tongue epithelium and the mesenchyme.
    [Show full text]
  • FGF/FGFR Signaling in Health and Disease
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN FGF/FGFR signaling in health and disease Yangli Xie1, Nan Su1, Jing Yang1, Qiaoyan Tan1, Shuo Huang 1, Min Jin1, Zhenhong Ni1, Bin Zhang1, Dali Zhang1, Fengtao Luo1, Hangang Chen1, Xianding Sun1, Jian Q. Feng2, Huabing Qi1 and Lin Chen 1 Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostasis by regulating cellular lineage commitment, differentiation, proliferation, and apoptosis of various types of cells. In this review, we provide a comprehensive overview of the current understanding of FGF signaling and its roles in organ development, injury repair, and the pathophysiology of spectrum of diseases, which is a consequence of FGF signaling dysregulation, including cancers and chronic kidney disease (CKD). In this context, the agonists and antagonists for FGF-FGFRs might have therapeutic benefits in multiple systems. Signal Transduction and Targeted Therapy (2020) 5:181; https://doi.org/10.1038/s41392-020-00222-7 INTRODUCTION OF THE FGF/FGFR SIGNALING The binding of FGFs to the inactive monomeric FGFRs will Fibroblast growth factors (FGFs) are broad-spectrum mitogens and trigger the conformational changes of FGFRs, resulting in 1234567890();,: regulate a wide range of cellular functions, including migration, dimerization and activation of the cytosolic tyrosine kinases by proliferation, differentiation, and survival. It is well documented phosphorylating the tyrosine residues within the cytosolic tail of that FGF signaling plays essential roles in development, metabo- FGFRs.4 Then, the phosphorylated tyrosine residues serve as the lism, and tissue homeostasis.
    [Show full text]
  • Halotag Is an Effective Expression and Solubilisation Fusion Partner for a Range of Fibroblast Growth Factors
    HaloTag is an eVective expression and solubilisation fusion partner for a range of fibroblast growth factors Changye Sun1,3 , Yong Li1,3 , Sarah E. Taylor1, Xianqing Mao2, Mark C. Wilkinson1 and David G. Fernig1 1 Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, UK 2 Department of Oncology, Laboratory of Cellular and Molecular Oncology, Luxembourg Institute of Health, Luxembourg 3 These authors contributed equally to this work. ABSTRACT The production of recombinant proteins such as the fibroblast growth factors (FGFs) is the key to establishing their function in cell communication. The production of recombinant FGFs in E. coli is limited, however, due to expression and solubility problems. HaloTag has been used as a fusion protein to introduce a genetically- encoded means for chemical conjugation of probes. We have expressed 11 FGF proteins with an N-terminal HaloTag, followed by a tobacco etch virus (TEV) protease cleavage site to allow release of the FGF protein. These were purified by heparin-aYnity chromatography, and in some instances by further ion-exchange chromatography. It was found that HaloTag did not adversely aVect the expression of FGF1 and FGF10, both of which expressed well as soluble proteins. The N-terminal HaloTag fusion was found to enhance the expression and yield of FGF2, FGF3 and FGF7. Moreover, whereas FGF6, FGF8, FGF16, FGF17, FGF20 and FGF22 were only expressed as insoluble proteins, their N-terminal HaloTag fusion counterparts (Halo-FGFs) were soluble, and could be successfully purified. However, cleavage of Halo-FGF6, -FGF8 and -FGF22 with TEV resulted in aggregation of the FGF protein.
    [Show full text]
  • Dissertation LFS Corrected 08-22-16
    EXPRESSION AND ROLE OF FIBROBLAST GROWTH FACTOR 9 (FGF9) IN BOVINE FOLLICULOGENESIS By LUÍS FERNANDO SCHÜTZ Doctor of Veterinary Medicine Federal University of Rio Grande do Sul Porto Alegre, Brazil 2007 Master of Science in Animal Science Santa Catarina State University Lages, Brazil Submitted to the Faculty of the Graduate College of the Oklahoma State University in partial fulfillment of the requirements for the Degree of DOCTOR OF PHILOSOPHY July, 2016 EXPRESSION AND ROLE OF FIBROBLAST GROWTH FACTOR 9 (FGF9) IN BOVINE FOLLICULOGENESIS Dissertation Approved: Dr. Leon J. Spicer Dissertation Adviser Dr. Robert Wettemann Dr. Glenn Zhang Dr. Peter Hoyt ii ACKNOWLEDGEMENTS To my beloved wife, for her love, support, encouragement, and understanding. She made all the steps of the arduous pathway to achieve this degree much easier. With her by my side, I feel much stronger. To my family in Brazil: my beloved parents, my brother, Lipe, and my sister, Ane, for their love, faith, and support. And to my beautiful niece, Sofia, my sister-in-law, Manuela, and my brother-in-law, Joni. To my advisor and mentor, Dr. Leon Spicer, for accepting me as a student, for giving me priceless lessons and advice whenever I needed, for stimulating me to develop a critical thinking, and for teaching me how to perform sound science in the field of ovarian folliculogenesis. And to his family, Michael, Melissa, Anna, and Richie, for their friendship and support. To the Franceschi family: my mother-in-law, Pierina, and my father-in-law, Adi, for their support and encouragement; to my brother-in-law, Junior, his wife, Janine, and his great boys, Bernardo and Bruno; and to my sister-in-law, Sheila, and her fiancé, Fábio.
    [Show full text]
  • Cancer Genomics and Genetics of FGFR2 (Review)
    233-237 1/7/08 14:49 Page 233 INTERNATIONAL JOURNAL OF ONCOLOGY 33: 233-237, 2008 233 Cancer genomics and genetics of FGFR2 (Review) MASARU KATOH Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received May 9, 2008; Accepted June 4, 2008 DOI: 10.3892/ijo_00000001 Abstract. FGFR2 gene encodes FGFR2b in epithelial cells, 6. Therapeutics targeted to FGFR and FGFR2c in mesenchymal cells. FGFR2b is a high affinity 7. Perspectives receptor for FGF1, FGF3, FGF7, FGF10 and FGF22, while FGFR2c for FGF1, FGF2, FGF4, FGF6, FGF9, FGF16 and FGF20. Here genomics and genetics of FGFR2, and thera- 1. Introduction peutics targeted to FGFR2 will be reviewed. Single nucleotide polymorphisms (SNPs) of FGFR2 are associated with increased FGF1, FGF2, FGF3, FGF4, FGF5, FGF6, FGF7 (KGF), risk of breast cancer. Gene amplification or missense mutation FGF8, FGF9, FGF10, FGF16, FGF17, FGF18, FGF19, of FGFR2 occurs in gastric cancer, lung cancer, breast cancer, FGF20, FGF21, FGF22, and FGF23 are secreted proteins ovarian cancer, and endometrial cancer. Genetic alterations belonging to the fibroblast growth factor (FGF) family (1,2). of FGFR2 induce aberrant FGFR2 signaling activation due to Mouse and rat ‘Fgf19’ are designated Fgf15 due to the lineage release of FGFR2 from autoinhibition, or creation of FGF specific protein diversification of FGF19 orthologs in rodents signaling autocrine loop. Class switch of FGFR2b to FGFR2c (3). FGF signals regulate a variety of cellular processes during is associated with more malignant phenotype. FGF and embryogenesis, adult tissue homeostasis, and carcinogenesis canonical WNT signals synergize during mammary carcino- (4-7).
    [Show full text]
  • Role of Fibroblast Growth Factor Receptor
    isorder D s & tic a T e h r e c r a n p a y Vescarelli et al., Pancreat Disord Ther 2015, 5:3 P Pancreatic Disorders & Therapy DOI: 10.4172/2165-7092.1000164 ISSN: 2165-7092 Case Report Open Access Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer: Potential Target for New Therapeutic Approach? Enrica Vescarelli1, Simona Ceccarelli1 and Antonio Angeloni2* 1Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, Rome, Italy 2Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena, Rome, Italy *Corresponding author: Antonio Angeloni, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy, Tel: +390649973012; E-mail: [email protected] Rec date: Oct 30, 2015; Acc date: Nov 20, 2015; Pub date: Nov 23, 2015 Copyright: ©2015 Vescarelli E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Fibroblast growth factors and their receptors play a key role in cell proliferation, migration and differentiation. Fibroblast growth factor receptor 2 (FGFR2) is involved in carcinogenesis and its altered expression has been shown in several tumors, such as breast, thyroid and pancreatic cancer. The two isoforms of FGFR2 gene, FGFR2- IIIb (also known as KGFR) and FGFR2-IIIc have been shown to exert differential roles in pancreatic cancer. FGFR2- IIIc supports pancreatic cell proliferation, while overexpression of FGFR2-IIIb is correlated to major invasion and metastasis formation.
    [Show full text]
  • Distinct Sets of FGF Receptors Sculpt Excitatory and Inhibitory
    © 2015. Published by The Company of Biologists Ltd | Development (2015) 142, 1818-1830 doi:10.1242/dev.115568 RESEARCH ARTICLE Distinct sets of FGF receptors sculpt excitatory and inhibitory synaptogenesis Ania Dabrowski1,2,3,4, Akiko Terauchi1,4, Cameron Strong4 and Hisashi Umemori1,2,3,4,5,* ABSTRACT Sanes and Yamagata, 2009; Shen and Scheiffele, 2010; Siddiqui Neurons in the brain must establish a balanced network of excitatory and Craig, 2011; Williams and Umemori, 2014; Williams et al., and inhibitory synapses during development for the brain to function 2010). An imbalance between excitatory and inhibitory drive in the properly. An imbalance between these synapses underlies various brain may lead to various neurological and psychiatric diseases, neurological and psychiatric disorders. The formation of excitatory including epilepsy, autism and schizophrenia (Lisman, 2012; and inhibitory synapses requires precise molecular control. In the Southwell et al., 2014). Thus, the components of molecular hippocampus, the structure crucial for learning and memory, signaling mediating synapse formation are key factors in the fibroblast growth factor 22 (FGF22) and FGF7 specifically promote vulnerability or resilience to such disorders. Hippocampal circuits excitatory or inhibitory synapse formation, respectively. Knockout of are crucial for memory formation, emotional processing and social either Fgf gene leads to excitatory-inhibitory imbalance in the mouse behavior. The hippocampal circuits consist of highly organized hippocampus and manifests in an altered susceptibility to epileptic synaptic connections, in which excitatory projections relay from the seizures, underscoring the importance of FGF-dependent synapse entorhinal cortex (EC) to the dentate gyrus (DG) to CA3 to CA1 to formation. However, the receptors and signaling mechanisms by the EC, and are balanced by inhibitory inputs from local which FGF22 and FGF7 induce excitatory and inhibitory synapse interneurons.
    [Show full text]
  • The Roles of Fibroblast Growth Factor 22 in Development, Tissue Repair and Homeostasis, and the Associated Role of FGF Signalling in Skin Cancer
    The roles of Fibroblast Growth Factor 22 in development, tissue repair and homeostasis, and the associated role of FGF signalling in skin cancer. Monika Jarosz This thesis is submitted in fulfilment of the requirements for the degree of Doctor of Philosophy University of London February 2010 Centre for Tumour Biology, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK DECLARATION OF AUTHORSHIP I hereby declare that the material presented in this thesis is the result of original work done by the author, Monika Jarosz, at the Department of Tumour Biology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London. All external sources have been properly acknowledged. 2 Abstract Fibroblast Growth Factors (FGFs) play critical roles during development, tissue homeostasis and repair and in controlling cell proliferation, survival, migration and differentiation. Of the 22 mammalian FGFs, FGF22, a member of the FGF7/10/22 subfamily, is relatively understudied. I have investigated the in vivo functions of FGF22 in mice engineered to lack Fgf22. Fgf22 null animals were viable, fertile and did not display any obvious abnormalities. No differences in skin histology and pelage hair were observed, demonstrating that FGF22 is dispensable during embryogenesis and in unchallenged adult skin. Mice lacking FGF22 were able to heal acute wounds just as efficiently as wild type mice. However, classical two-step skin carcinogenesis challenge revealed that Fgf22 null mice developed considerably less papillomas than wild type mice. Interestingly, Fgf22 knockout mice displayed a significant reduction in body weight and I identified several novel sites of Fgf22 expression in the gastrointestinal tract.
    [Show full text]